1.Patients or their legal guardians must voluntarily participate and sign an informed consent form.

2.Female patients aged between 18 and 70 years.

3. ECOG performance status S2, life expectancy of>12 weeks

4. Patients must have a pathological diagnosis of ovarian cancer, including epithelial, germ cell, sex cord-stromal tumors, or other pathological types, with HER2 expression confirmed to be ≥ 210% using immunohistochemistry.

5. Patients must have been diagnosed with ovarian cancer and received at least first-line treatment, including disease recurrence/progression during first-line treatment. Recurrence/progression is defined as follows (meeting any of the following criteria):

a. Clear documentation of progression in imaging studies.

b. Continuous elevation of CA125 levels (confirmed one week later) accompanied by clinical symptoms or physical examination findings indicative of disease progression.

6. Patients must have measurable or evaluable disease (ascites is a mandatory requirement), with at least one lesion having a precise measurement diameter (according to RECIST V11 criteria, the lesion should have a longitudinal diameter of 210 mm on spiral CT scans or a short-axis diameter of 215 mm for enlarged lymph nodes). For lesions that have previously undergone local treatment, they can only be considered measurable lesions if there is confirmed progression according to RECIST V1.1.

Patients who have received the following anti-tumor treatments before apheresis:

a. Cytotoxic therapy within the past 14 days.

b. Experimental drug therapy within the past 28 days (if the treatment was also experimental, a 28-day washout period is required).

c. Immune modulatory therapy within the past 7 days.

d. Targeted therapy within the past 28 days.

Patients with a history of receiving CAR-T cell therapy targeting any antigen, other cell-based therapy, or therapeutic cancer vaccines.

Patients with infectious diseases such as HIV, active hepatitis B or C infection, active tuberculosis, etc.

Patients with significant underlying diseases, including:

a. Evidence of severe active viral or bacterial infections or uncontrolled systemic fungal infections.

b. Active or unstable autoimmune diseases or a history of autoimmune diseases within the past 3 years with the potential for recurrence.

c. Clear clinical evidence of dementia or changes in mental status.

Patients with a highly allergic disposition or a history of severe allergies.

Patients with impaired function of vital organs, including the heart, lungs, brain, liver, or kidneys.

Patients with a history of gastrointestinal perforation, intra-abdominal abscess, or recent (within the past 3 months) bowel obstruction, or with imaging or clinical symptoms suggestive of bowel obstruction.

Patients with poorly controlled clinical cardiac symptoms or diseases, such as:

a. New York Heart Association (NYHA) Class 2 or higher heart failure.

b. Unstable angina.

c. Myocardial infarction within the past year.

d. Clinically significant atrial or ventricular arrhythmias requiring treatment or intervention.

e. PR interval >250ms or QTc >250ms.

Patients with abnormal coagulation function (INR >2.0 or prothrombin time PT >16s) with a bleeding tendency or receiving thrombolytic or anticoagulation therapy (prophylactic use of low-dose aspirin or low-molecular-weight heparin is allowed).

Patients with chronic diseases requiring systemic corticosteroids or other immunosuppressive therapy who have received systemic corticosteroids (≥30 mg of prednisone or equivalent) or other immunosuppressive therapy within 30 days before apheresis, except for the following situations: use of topical, ocular, intra-articular, intranasal, or inhaled corticosteroids; short-term use of corticosteroids for prophylactic purposes (e.g., prevention of contrast agent allergies).

Patients whose toxic reactions from previous anti-tumor treatments have not recovered to Grade ≤1 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE 5.0), except for hair loss or Grade 2 peripheral neuropathy.

Patients previously diagnosed with or treated for malignant tumors other than epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

Pregnant or lactating women, or women planning pregnancy within six months.